Cannabidiol In Clinical Practice: Scientific Evidence, Therapeutic Applications And Regulatory Challenges
Cannabidiol In Clinical Practice: Scientific Evidence, Therapeutic Applications And Regulatory Challenges
DOI:
https://doi.org/10.51473/rcmos.v1i1.2026.2124Keywords:
cannabidiol, endocannabinoid system, refractory epilepsyAbstract
Cannabidiol (CBD), a phytocannabinoid derived from Cannabis sativa, has been attracting increasing interest in contemporary clinical practice. This structured narrative review synthesizes scientific evidence on clinical applications, safety, drug interactions, and Brazilian regulatory aspects. Robust evidence supports its use in refractory epilepsies, especially in Dravet and Lennox-Gastaut syndromes. In chronic pain, spasticity, and anxiety, the data are heterogeneous. It is concluded that CBD should be used in an individualized manner, with clinical monitoring and scientific basis.
Downloads
References
Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond). 2006;30(Suppl 1):S13-8.
World Health Organization (WHO). Cannabidiol (CBD) Critical Review Report. Expert Committee on Drug Dependence. Geneva: WHO; 2018.
Mechoulam R, Shvo Y. Hashish—I: The structure of cannabidiol. Tetrahedron. 1963;19(12):2073-8.
Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(Suppl 1):S163-71.
Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008;29(2):192-200.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016;112:119-27.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-20.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888-97.
Thiele EA, Marsh ED, French JA, Mazurkiewicz MB, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-96.
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-73.
Agência Nacional de Vigilância Sanitária (ANVISA). Resolução da Diretoria Colegiada – RDC nº 327, de 9 de dezembro de 2019. Dispõe sobre os procedimentos para a concessão da Autorização Sanitária para fabricação e importação, bem como estabelece requisitos para comercialização, prescrição e dispensação de produtos à base de Cannabis para fins medicinais. Diário Oficial da União. 2019.
Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-26.
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845-52.
Zendulka O, Dovrtělová G, Nosková K, Turjap M, Sulcová A, Hanuš L, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17(3):206-26.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Erickson Danilo Padovani, Weslei Douglas Leite da Silva (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
